» Articles » PMID: 19960435

The Polyamine Metabolism Genes Ornithine Decarboxylase and Antizyme 2 Predict Aggressive Behavior in Neuroblastomas with and Without MYCN Amplification

Overview
Journal Int J Cancer
Specialty Oncology
Date 2009 Dec 5
PMID 19960435
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

High polyamine (PA) levels and ornithine decarboxylase (ODC) overexpression are well-known phenomena in many aggressive cancer types. We analyzed the expression of ODC and ODC-activity regulating genes antizymes 1-3 (OAZ1-3) and antizyme inhibitors 1-2 (AZ-IN1-2) in human neuroblastoma (NB) tumors and correlated these with genetic and clinical features of NB. Since ODC is a known target gene of MYCN, the correlation between ODC and MYCN was of special interest. Data were obtained from Affymetrix micro-array analysis of 88 NB tumor samples. In addition, mRNA expression levels of ODC, OAZ2 and MYCN in a MYCN-inducible NB cell line were determined by quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR). ODC mRNA expression in NB tumors was significantly predictive of decreased overall survival probability and correlated with several unfavorable clinical NB characteristics (all p < 0.005). Interestingly, high ODC mRNA expression also showed significant correlation with poor survival prognosis in Kaplan-Meier analyses stratified for patients without MYCN amplification, suggesting an additional role for ODC independent of MYCN. Conversely, high OAZ2 mRNA expression correlated with increased survival and with several favorable clinical NB characteristics (all p < 0.003). In addition, we provide first evidence of a role for MYCN-associated transcription factors MAD2 and MAD7 in ODC regulation. In NB cell cultures, ectopic overexpression of MYCN altered ODC but not OAZ2 mRNA levels. In conclusion, these data suggest that elevated ODC and low OAZ2 mRNA expression levels correlate with several unfavorable genetic and clinical features in NB, offering new insights into PA pathways and PA metabolism-targeting therapy in NB.

Citing Articles

Ornithine decarboxylase antizyme 2 (OAZ2) in human colon adenocarcinoma: a potent prognostic factor associated with immunity.

Liu Y, Zhang S, Liao W, Qian J, Lu C, Jin L Sci Rep. 2025; 15(1):7481.

PMID: 40032914 PMC: 11876682. DOI: 10.1038/s41598-025-90066-4.


Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy.

Schramm J, Sholler C, Menachery L, Vazquez L, Saulnier Sholler G J Clin Med. 2025; 14(4).

PMID: 40004600 PMC: 11856405. DOI: 10.3390/jcm14041068.


The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma.

Azfar M, Gao W, Van den Haute C, Xiao L, Karsa M, Pandher R Mol Oncol. 2025; 19(3):913-936.

PMID: 39981745 PMC: 11887671. DOI: 10.1002/1878-0261.13789.


Construction of molecular subtype and prognostic model for gastric cancer based on nucleus-encoded mitochondrial genes.

Wang X, Li S, Shen Y, Cao L, Lu Y, Cao J Sci Rep. 2024; 14(1):28491.

PMID: 39557952 PMC: 11574080. DOI: 10.1038/s41598-024-78729-0.


Bachmann-Bupp syndrome and treatment.

Bachmann A, VanSickle E, Michael J, Vipond M, Bupp C Dev Med Child Neurol. 2023; 66(4):445-455.

PMID: 37469105 PMC: 10796844. DOI: 10.1111/dmcn.15687.


References
1.
Albeck S, Dym O, Unger T, Snapir Z, Bercovich Z, Kahana C . Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci. 2008; 17(5):793-802. PMC: 2327289. DOI: 10.1110/ps.073427208. View

2.
Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P . The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res. 2008; 314(4):707-19. DOI: 10.1016/j.yexcr.2007.12.008. View

3.
Lutz W, Stohr M, SCHURMANN J, Wenzel A, Lohr A, Schwab M . Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996; 13(4):803-12. View

4.
Cohn S, London W, Huang D, Katzenstein H, Salwen H, Reinhart T . MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000; 18(21):3604-13. DOI: 10.1200/JCO.2000.18.21.3604. View

5.
Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A . The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A. 2005; 102(3):731-6. PMC: 545522. DOI: 10.1073/pnas.0405495102. View